GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of GH Research PLC (NASDAQ:GHRS) have been given a consensus rating of “Moderate Buy” by the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $33.1111.

A number of analysts have issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of GH Research in a research note on Tuesday. Needham & Company LLC set a $29.00 target price on shares of GH Research in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Wednesday, October 8th. Cowen restated a “buy” rating on shares of GH Research in a research note on Monday. Finally, Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th.

GH Research Price Performance

Shares of GHRS opened at $17.95 on Thursday. The firm has a 50-day simple moving average of $13.83 and a two-hundred day simple moving average of $13.78. The stock has a market cap of $933.94 million, a PE ratio of -24.26 and a beta of 0.98. GH Research has a 1-year low of $7.98 and a 1-year high of $20.50.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23). As a group, sell-side analysts expect that GH Research will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

A number of institutional investors and hedge funds have recently modified their holdings of GHRS. Osaic Holdings Inc. increased its stake in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of GH Research in the 2nd quarter valued at $79,000. Virtus Investment Advisers LLC purchased a new position in shares of GH Research in the 2nd quarter valued at $89,000. BNP Paribas Financial Markets raised its stake in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after acquiring an additional 10,600 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its position in GH Research by 68.2% in the second quarter. Palumbo Wealth Management LLC now owns 21,651 shares of the company’s stock valued at $264,000 after acquiring an additional 8,782 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.